Basic, Translational and Clinical Research on Dementia—Second Edition
A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Neurobiology".
Deadline for manuscript submissions: 20 April 2025 | Viewed by 205
Special Issue Editors
Interests: pharmacology; neurotherapeutics; brain ischemia; glaucoma; pain; herbal medicines
Special Issues, Collections and Topics in MDPI journals
Interests: basic and translational research; neurotherapeutics; neurorehabilitation; dementia; pain; migraine; natural products
Special Issues, Collections and Topics in MDPI journals
Interests: Alzheimer; dementia; epigenetics; aging
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
The global impact of dementia is increasingly worrisome, and up to 90% of dementia patients in low- and middle-income countries are not diagnosed, with further delays in diagnosis occurring due to the COVID-19 pandemic, during which these fragile populations paid the highest price.
Alzheimer’s disease (AD) is the most common neurodegenerative disease, accounting for about two-thirds of all cases, but mixed forms of dementia are being increasingly recognized, making dementia a public health priority. These different forms may at least in part be explained through progressive alterations in the epigenome that may contribute to the decrease in cognitive abilities with advancing age.
Indeed, there is little doubt that AD is a multifactorial disease, which involves diverse pathogenic mechanisms and will probably require combinatorial therapies. Although many pathological factors, such as the accumulation of protein aggregates of amyloid-beta (Aβ) and tau, have been identified, their role in combination with other factors, at different disease stages, requires further clarification. A comprehensive understanding of the complex disease mechanisms and the identification of early disease markers aided by ultrastructural magnetic resonance imaging are necessary to develop more effective treatments.
Although multiple failures of phase III trials with agents targeting Aβ had initially been disappointing, the accelerated approval of mAbs has recently renewed interest in targeting Aβ. The gain of information from real-world data on these neurotherapeutics may anticipate that the further development of clinical trials in AD will be prompted.
Accordingly, we would like to invite contributions from basic, translational, and clinical research on dementia in the form of original, narrative, or systematic reviews on each of the abovementioned topics.
Prof. Dr. Giacinto Bagetta
Dr. Damiana Scuteri
Dr. Daniele Bano
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- dementia
- Alzheimer’s disease
- amyloid-beta
- tau protein
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
